FSHD region gene 2 family member H, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FRG2HP profile across patient tissues and cancer cell-line models. FRG2HP expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FRG2HP is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, FRG2HP RNA expression shows 6,539 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BRCA, and STAD as cancer lineages where FRG2HP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG2HP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG2HP survival associations across molecular data types. FRG2HP RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG2HP RNA expression–survival associations across cancer types. High FRG2HP expression shows unfavorable associations in ACC, KIRC, THCA, LAML, LUAD and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FRG2HP RNA expression.
This table summarizes FRG2HP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FRG2HP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG2HP shows lower tumor expression in BRCA and KIRC and higher tumor expression in LUAD, LUSC and THCA. The BRCA box plot shows higher FRG2HP RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .002).
This table shows molecular features associated with FRG2HP in patient tissues and cancer cell lines. In patient samples, FRG2HP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
